Burkina Faso

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Sanofi-aventis: My Child Matters

In 2004, sanofi-aventis and the International Union Against Cancer (UICC) launched a mobilization and awareness program called 'My Child Matters', to fight against childhood cancers in emerging countries. The objective is to encourage institutions (hospitals, NGOs, etc.) to develop pragmatic approaches to improve awareness, early diagnosis, access to care and treatment, pain control and better management of the social and cultural aspects of the disease for both children and families.

Sanofi-aventis: Impact Malaria

The Impact Malaria program embodies sanofi-aventis' longstanding commitment to fight malaria. Sanofi-aventis is researching new treatments that are affordable, adapted to patients' needs, especially children, and can help circumvent growing resistance to existing medicines. The most advanced projects are ferroquine for uncomplicated malaria, developed with Lille University and 'bicationic compounds' for severe malaria with Montpellier University, both in Phase II clinical trials. Upstream projects include development of 'trioxaquins' with Palumed in Toulouse.

Sanofi-aventis Children's Programs

Sanofi-aventis supports a number of projects in developing countries, the main purpose of which is to help improve children's health.

Sanofi-aventis & EPIVAC

EPIVAC (from EPIdemiology & VACcinology) is a comprehensive, one-year, on-the-job professional training program in epidemiology, applied computing, vaccinology and management of health programs for public health officers in West Africa, culminating in an inter-university diploma in 'Organization and Management of Public Immunization Programs in Developing Countries' awarded by the universities of Cocody-Abidjan (Ivory Coast) and Paris-Dauphine (France). The program is a Sanofi Pasteur, the vaccines division of sanofi-aventis, contribution to the GAVI Alliance.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Pfizer - Azithromycin/chloroquine for Malaria

Pfizer, in partnership with Medicines for Malaria Venture (MMV) and London School of Hygiene and Tropical Medicine, is developing a fixed dose combination of azithromycin and chloroquine (AZCQ) for intermittent treatment of malaria in pregnant women (IPTp) in sub-Saharan Africa. IPTp is aimed at lowering the incidence of adverse pregnancy outcomes associated with malaria in pregnancy. Sulfadoxine/pyrimethamine (SP) is the current standard of care for IPTp in high transmission areas in Africa.

PATH Malaria Vaccine Initiative (MVI)

MVI works to link government, industry, and academia partners with field trial sites in malaria endemic countries as early as feasible in the development process.

Novo Nordisk: Differential Pricing on Insulin

Among the targets for UN Millennium Development Goal 8 is a call for partnerships with pharmaceutical companies to provide access to affordable essential drugs in developing countries. Since 2001, Novo Nordisk has offered human insulin to the public health systems in Least Developed Countries (LDCs) at prices which do not to exceed 20% of the average price in Europe, Japan and North America. In 2009, Novo Nordisk offered this pricing scheme to all 49 LDCs, of which 36 used it to buy insulin at or below this price, compared to 32 in 2008.

Pages